These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 26583301)

  • 1. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
    Kumar VA; Wilson SS; Ayaz SI; Levy PD
    Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
    Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
    Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serelaxin : a potential new drug for the treatment of acute heart failure.
    Neverova N; Teerlink JR
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serelaxin a novel treatment for acute heart failure.
    Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
    Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relaxin: a novel agent for the treatment of acute heart failure.
    Wilson SS; Ayaz SI; Levy PD
    Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
    Ng TM; Goland S; Elkayam U
    Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Serelaxin in Patients with Acute Heart Failure.
    Metra M; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Voors AA; Adams KF; Anker SD; Arias-Mendoza A; Avendaño P; Bacal F; Böhm M; Bortman G; Cleland JGF; Cohen-Solal A; Crespo-Leiro MG; Dorobantu M; Echeverría LE; Ferrari R; Goland S; Goncalvesová E; Goudev A; Køber L; Lema-Osores J; Levy PD; McDonald K; Manga P; Merkely B; Mueller C; Pieske B; Silva-Cardoso J; Špinar J; Squire I; Stępińska J; Van Mieghem W; von Lewinski D; Wikström G; Yilmaz MB; Hagner N; Holbro T; Hua TA; Sabarwal SV; Severin T; Szecsödy P; Gimpelewicz C;
    N Engl J Med; 2019 Aug; 381(8):716-726. PubMed ID: 31433919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serelaxin and acute heart failure.
    Tietjens J; Teerlink JR
    Heart; 2016 Jan; 102(2):95-9. PubMed ID: 26603680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
    Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
    Díez J; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
    Schmieder RE; Mitrovic V; Hengstenberg C
    Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.
    Metra M; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld L; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Prescott MF; Edwards C; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin T; Teerlink JR;
    J Am Coll Cardiol; 2013 Jan; 61(2):196-206. PubMed ID: 23273292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter, Randomized, Double-Blinded, Placebo-Controlled Phase II Study of Serelaxin in Japanese Patients With Acute Heart Failure.
    Sato N; Takahashi W; Hirayama A; Ajioka M; Takahashi N; Okishige K; Wang X; Maki A; Maruyama H; Ebinger U; Yamaguchi M; Pang Y; Matsumoto H; Kawana M
    Circ J; 2015; 79(6):1237-47. PubMed ID: 25912697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serelaxin: a novel therapy for acute heart failure with a range of hemodynamic and non-hemodynamic actions.
    Díez J
    Am J Cardiovasc Drugs; 2014 Aug; 14(4):275-85. PubMed ID: 24590581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF.
    Liu LC; Voors AA; Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Chen Y; Greenberg BH; Ponikowski P; Pang PS; Prescott MF; Hua TA; Severin TM; Metra M
    Clin Res Cardiol; 2016 Sep; 105(9):727-37. PubMed ID: 27017514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.
    Felker GM; Teerlink JR; Butler J; Hernandez AF; Miller AB; Cotter G; Davison BA; Filippatos G; Greenberg BH; Ponikowski P; Voors AA; Hua TA; Severin TM; Unemori E; Metra M
    J Am Coll Cardiol; 2014 Oct; 64(15):1591-8. PubMed ID: 25301463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
    Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
    Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.
    Dahlke M; Ng D; Yamaguchi M; Machineni S; Berger S; Canadi J; Rajman I; Lloyd P; Pang Y
    J Clin Pharmacol; 2015 Apr; 55(4):415-22. PubMed ID: 25408331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Representativeness of RELAX-AHF clinical trial population in acute heart failure.
    Wang TS; Hellkamp AS; Patel CB; Ezekowitz JA; Fonarow GC; Hernandez AF
    Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):259-68. PubMed ID: 24594552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of serelaxin when added to standard of care in patients with acute heart failure: results from a PROBE study, RELAX-AHF-EU.
    Maggioni AP; López-Sendón J; Nielsen OW; Hallén J; Aalamian-Mattheis M; Wang Y; Ertl G
    Eur J Heart Fail; 2019 Mar; 21(3):322-333. PubMed ID: 30604559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.